Ultrafast diagnosis of epilepsy: a randomised controlled trial of AI-assisted interpretation of ambulatory EEG recordings versus routine care. - AI-assisted diagnosis of epilepsy

开始日期2024-10-03

申办/合作机构

Medisch Spectrum Twente

NCT06480084 / Not yet recruitingN/A

The Prevalence of Exercise-Induced Laryngeal Obstruction (EILO) Amongst Children With Asthma' - a Prospective Cross-sectional Study

The goal of this cross-sectional study is to investigate the prevalence of Exercise Induced Laryngeal Obstruction (EILO) in children with asthma.
The hypothesis is that the prevalence will be around 15%, which is higher than the prevalence of 5-8% among the general adolescent population. This is based on the increased prevalence of EILO among adult asthmatics.
Participants who are referred for an Exercise Challenge Test will perform an additional Continuous Laryngoscopy during Exercise Test with expiratory FEV1 curves, and fill in the Borg scale for dyspnea, Asthma Control Test, EILODI questionnaire and DISCO-RC questionnaire.

开始日期2024-08-01

申办/合作机构

Medisch Spectrum Twente

[+1]

NL-OMON56861 / RecruitingN/A

Effectiveness of Virtual Reality for chronic pain in patients with inflammatory arthritis; a randomized controlled pragmatic clinical trial - VIRTUAL trial

开始日期2024-07-16

申办/合作机构

Medisch Spectrum Twente

100 项与 Medisch Spectrum Twente 相关的临床结果

登录后查看更多信息

0 项与 Medisch Spectrum Twente 相关的专利（医药）

登录后查看更多信息

1,943

项与 Medisch Spectrum Twente 相关的文献（医药）

2024-08-01·European Journal of Vascular and Endovascular Surgery

Axillo-Superior Mesenteric Artery–Bifemoral Bypass: An Extraordinary Bypass!

Article

作者: Metz, Flores M ; Daans, Jaleesa R E

2024-06-01·Journal of Plastic, Reconstructive & Aesthetic Surgery

Patient-reported esthetic outcomes following lower extremity free flap reconstruction: A cross-sectional multicenter study

Article

作者: Rakhorst, Hinne A ; List, Emile B ; Maarse, Wiesje ; Verheul, Elfie M ; de Jong, Tim ; Krijgh, David D ; Coert, J Henk ; Qiu Shao, Shan S ; Beljaars, Brent

INTRODUCTIONThe goal of lower-extremity reconstructions is primarily to salvage the leg; however, esthetic outcomes are also important. This study aimed to assess the impact of a lower extremity free tissue transfer regarding social functioning, patient-reported esthetic outcomes, and possible differences between fasciocutaneous vs. muscle flaps.MATERIAL AND METHODSFor this cross-sectional multicenter study, patients operated between 2003 and 2021, with a minimum follow-up of 12 months, were identified. Outcomes were obtained from 89 patients. Patient-reported outcomes were assessed using a questionnaire containing 5-point Likert scale questions grouped in three groups: aspect of the reconstructed leg, the aspect of the donor site, and the negative impact on social functioning. Physical functioning and mental health were assessed with the Short-Form-36.RESULTSThe overall score for negative impact on social functioning was 22.2. This was 46.7 for the esthetic satisfaction of the reconstructed leg and 57.1 for the donor site. No significant differences were seen between patients who underwent a reconstruction with a fasciocutaneous flap compared to a muscle flap. Secondary surgical procedures for improving the esthetic aspect were performed in 12% of the patients in the fasciocutaneous group and 0% in the muscle group.CONCLUSIONOur results show that the most optimal esthetic outcome is not defined by the type of flap. We found a strong correlation between physical functioning and the negative impact on social functioning that a reconstructed lower extremity may have. The result of this study can be taken into consideration during the shared decision-making process of choosing the most optimal reconstruction.

2024-05-01·Gut

Standardised training for endoscopic mucosal resection of large non-pedunculated colorectal polyps to reduce recurrence (*STAR-LNPCP study): a multicentre cluster randomised trial

Article

作者: Thurnau, Karsten ; Schwartz, Matthijs P ; Vlug, Marije S ; Bogie, Roel M M ; de Vos Tot Nederveen Cappel, Wouter H ; Stoop, Esther ; Ramaker, Jos M ; van Leerdam, Monique E ; de Bruin, Gijs J ; Alderlieste, Yasser A ; Pellisé, María ; Marsman, Willem A ; Roberts-Bos, Linda ; Bourke, Michael J ; de Vries, Roland S ; Baven-Pronk, Martine ; Vogelaar, Lauran ; Bos, Philip ; Schrauwen, Ruud W M ; Moons, Leon M G ; Hazen, Wouter L ; Kuiper, Edith ; Wolfhagen, Frank H J ; Roomer, Robert ; Boersma, Femke ; de Ridder, Rogier J ; Winkens, Bjorn ; van der Voorn, Michael ; Groen, John ; van Nunen, Annick B ; Alvarez Herrero, Lorenza ; Masclee, Ad A M ; Schreuder, Ramon-Michel M ; Siersema, Peter D ; Seerden, Tom C J ; Bargeman, Marloes ; Vleggaar, Frank P ; de Bièvre, Marc ; Meulen, Lonne W T

ObjectiveEndoscopic mucosal resection (EMR) is the preferred treatment for non-invasive large (≥20 mm) non-pedunculated colorectal polyps (LNPCPs) but is associated with an early recurrence rate of up to 30%. We evaluated whether standardised EMR training could reduce recurrence rates in Dutch community hospitals.DesignIn this multicentre cluster randomised trial, 59 endoscopists from 30 hospitals were randomly assigned to the intervention group (e-learning and 2-day training including hands-on session) or control group. From April 2019 to August 2021, all consecutive EMR-treated LNPCPs were included. Primary endpoint was recurrence rate after 6 months.ResultsA total of 1412 LNPCPs were included; 699 in the intervention group and 713 in the control group (median size 30 mm vs 30 mm, 45% vs 52% size, morphology, site and access (SMSA) score IV, 64% vs 64% proximal location). Recurrence rates were lower in the intervention group compared with controls (13% vs 25%, OR 0.43; 95% CI 0.23 to 0.78; p=0.005) with similar complication rates (8% vs 9%, OR 0.93; 95% CI 0.64 to 1.36; p=0.720). Recurrences were more often unifocal in the intervention group (92% vs 76%; p=0.006). In sensitivity analysis, the benefit of the intervention on recurrence rate was only observed in the 20–40 mm LNPCPs (5% vs 20% in 20–29 mm, p=0.001; 10% vs 21% in 30–39 mm, p=0.013) but less evident in ≥40 mm LNPCPs (24% vs 31%; p=0.151). In a post hoc analysis, the training effect was maintained in the study group, while in the control group the recurrence rate remained high.ConclusionA compact standardised EMR training for LNPCPs significantly reduced recurrences in community hospitals. This strongly argues for a national dedicated training programme for endoscopists performing EMR of ≥20 mm LNPCPs. Interestingly, in sensitivity analysis, this benefit was limited for LNPCPs ≥40 mm.Trial registration numberNTR7477.

项与 Medisch Spectrum Twente 相关的新闻（医药）

2022-12-12

·GlobeNewswire-Health Care

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an “Ask the Expert” conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT). Prof Slakter is a board certified Retinal and Macular Disease Specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner of Vitreous Retina Macula Consultants of New York. Prof Slakter will present an overview of Opthea’s Phase 2b and Phase 3 clinical trial program followed by a Question and Answer session on the current management of wet AMD patients and the potential role of OPT-302 within the treatment landscape. Participants are invited to submit questions via this link prior to the conference call. Please click here to register for the virtual meeting which will be held via Zoom. About Opthea Limited Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone. Inherent risks of Investment in Biotechnology Companies There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments. Authorized for release to ASX by Megan Baldwin, CEO & Managing Director Company & Media Enquiries: U.S.A. & International:Timothy E. Morris, CFOOpthea LimitedTel: +1 650-400-6874 Australia:Rudi MichelsonMonsoon CommunicationsTel: +61 (0) 3 9620 3333 Media:Hershel BerryBlueprint Life Science GroupTel: +1 415 505 3749hberry@bplifescience.com Join our email database to receive program updates: Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com

临床3期临床2期

2021-06-24

·GlobeNewswire

E-commerce Home Fitness Products in Europe Market to Garner

Portland, OR, June 24, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the Europe e-commerce home fitness products market generated $256.1 million in 2019, and is estimated to garner $447.9 million by 2027, witnessing a CAGR of 5.9% from 2021 to 2027. The report provides a detailed analysis of changing market dynamics, top winning strategies, market size & forecasts, key segments, and competitive landscape. Increase in fitness awareness and health concerns and surge in obese population drive the growth of the Europe e-commerce home fitness products market. However, availability of refurbished products along with presence of counterfeit brands hinders the market growth. On the other hand, introduction of smart technologies present new opportunities in the coming years. Get detailed COVID-19 impact analysis on the Europe e-commerce home fitness products Industry @ Covid-19 Scenario: Download PDF Sample Report @ The report offers detailed segmentation of the Europe e-commerce home fitness products market based on equipment type and country. Based on equipment type, the cardiovascular training equipment segment held the largest market share, contributing to more than two-thirds of the total share in 2019, and is expected to continue its leadership status during the forecast period. However, the strength training equipment segment is expected to portray the largest CAGR of 7.1% from 2021 to 2027. For Purchase Enquiry @ Based on country, Germany contributed to the highest market share in 2019, accounting for nearly one-fourths of the market, and is estimated to maintain its lead position during the forecast period. Moreover, this segment is expected to manifest the fastest CAGR of 6.9% from 2021 to 2027. Leading players of the Europe e-commerce home fitness products market analyzed in the report include Johnson Fitness, MST GmbH, Hansson International GmbH, Jordan Leisure Systems Ltd., Bad Company, ISE GmbH, Sport Tiedje, Escape Ltd., Sport Thieme, Hammer Sports, Sporttec, Horizon Fitness, and Do Yoursports. Access AVENUE - A Subscription-Based Library (Premium On-Demand, Subscription-Based Pricing Model) @ Avenue is a user-based library of global market report database, provides comprehensive reports pertaining to the world's largest emerging markets. It further offers e-access to all the available industry reports just in a jiffy. By offering core business insights on the varied industries, economies, and end users worldwide, Avenue ensures that the registered members get an easy as well as single gateway to their all-inclusive requirements. Avenue Library Subscription | Request For 14 Days Free Trial of Before Buying: About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology incl

100 项与 Medisch Spectrum Twente 相关的药物交易

登录后查看更多信息

100 项与 Medisch Spectrum Twente 相关的转化医学

登录后查看更多信息